×
About 4,476 results

ALLMedicine™ Mastocytosis Center

Research & Reviews  1,913 results

Medical, neurobiological, and psychobehavioral perspectives of mastocytosis: a case rep...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8008611
Journal of Medical Case Reports; Héron A, Papillon V et. al.

Mar 30th, 2021 - Cutaneous mastocytosis is a rare pathology characterized by an abnormal proliferation and degranulation of mast cells, affecting the skin. Here we present the case of a patient suffering from chronic resistant mastocytosis. An original integrative...

Impaired endothelial function irrespective of systemic inflammation or atherosclerosis ...
https://doi.org/10.1016/j.anai.2021.03.020
Annals of Allergy, Asthma & Immunology : Official Publica... Oztop N, Ozer PK et. al.

Mar 29th, 2021 - Knowledge on endothelial dysfunction and its relation to atherosclerosis in mastocytosis is limited. To investigate the endothelial function in mastocytosis by flow mediated dilatation (FMD) and biomarkers related to vascular endothelia and to eva...

Imatinib for control of bullous skin lesions in a child with familial mastocytosis.
https://doi.org/10.1111/bjh.17455
British Journal of Haematology; Kendall J, Martinez A et. al.

Mar 27th, 2021 - Imatinib for control of bullous skin lesions in a child with familial mastocytosis.|2021|Kendall J,Martinez A,Bartram J,|

Routine KIT p.D816V screening identifies clonal mast cell disease in Hymenoptera allerg...
https://doi.org/10.1016/j.jaci.2021.02.043
The Journal of Allergy and Clinical Immunology; Šelb J, Rijavec M et. al.

Mar 23rd, 2021 - Clonal mast cell disorders and elevated BST of unknown cause(s) are associated with severe Hymenoptera venom-triggered anaphylaxis (HVA). However, some individuals with clonal disease have normal BST (<11.4 ng/mL). To evaluate whether screening fo...

Clonal evolution and heterogeneity in advanced systemic mastocytosis revealed by single...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7993095
Blood Advances; Lim KH, Wu JN et. al.

Mar 18th, 2021 - Clonal evolution and heterogeneity in advanced systemic mastocytosis revealed by single-cell DNA sequencing.|2021|Lim KH,Wu JN,Huang TY,Jhuang JY,Chang YC,|

see more →

Guidelines  3 results

Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2018.0088
Journal of the National Comprehensive Cancer Network : JN... Gotlib J, Gerds AT et. al.

Dec 13th, 2018 - Mastocytosis is a group of heterogeneous disorders resulting from the clonal proliferation of abnormal mast cells and their accumulation in the skin and/or in various extracutaneous organs. Systemic mastocytosis is the most common form of mastocyt...

Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
http://www.jnccn.org/content/16/12/1500.full
Gotlib, J.

Nov 30th, 2018 - Mastocytosis is a group of heterogeneous disorders resulting from the clonal proliferation of abnormal mast cells and their accumulation in the skin and/or in various extracutaneous organs. Systemic mastocytosis is the most common form of mastocyt.

Proposed diagnostic algorithm for patients with suspected mastocytosis: a proposal of t...
https://doi.org/10.1111/all.12436
Allergy Valent P, Escribano L et. al.

May 19th, 2014 - Mastocytosis is an emerging differential diagnosis in patients with more or less specific mediator-related symptoms. In some of these patients, typical skin lesions are found and the diagnosis of mastocytosis can be established. In other cases, ho...

see more →

Drugs  269 results see all →

Clinicaltrials.gov  2,225 results

Medical, neurobiological, and psychobehavioral perspectives of mastocytosis: a case rep...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8008611
Journal of Medical Case Reports; Héron A, Papillon V et. al.

Mar 30th, 2021 - Cutaneous mastocytosis is a rare pathology characterized by an abnormal proliferation and degranulation of mast cells, affecting the skin. Here we present the case of a patient suffering from chronic resistant mastocytosis. An original integrative...

Impaired endothelial function irrespective of systemic inflammation or atherosclerosis ...
https://doi.org/10.1016/j.anai.2021.03.020
Annals of Allergy, Asthma & Immunology : Official Publica... Oztop N, Ozer PK et. al.

Mar 29th, 2021 - Knowledge on endothelial dysfunction and its relation to atherosclerosis in mastocytosis is limited. To investigate the endothelial function in mastocytosis by flow mediated dilatation (FMD) and biomarkers related to vascular endothelia and to eva...

Imatinib for control of bullous skin lesions in a child with familial mastocytosis.
https://doi.org/10.1111/bjh.17455
British Journal of Haematology; Kendall J, Martinez A et. al.

Mar 27th, 2021 - Imatinib for control of bullous skin lesions in a child with familial mastocytosis.|2021|Kendall J,Martinez A,Bartram J,|

Routine KIT p.D816V screening identifies clonal mast cell disease in Hymenoptera allerg...
https://doi.org/10.1016/j.jaci.2021.02.043
The Journal of Allergy and Clinical Immunology; Šelb J, Rijavec M et. al.

Mar 23rd, 2021 - Clonal mast cell disorders and elevated BST of unknown cause(s) are associated with severe Hymenoptera venom-triggered anaphylaxis (HVA). However, some individuals with clonal disease have normal BST (<11.4 ng/mL). To evaluate whether screening fo...

Clonal evolution and heterogeneity in advanced systemic mastocytosis revealed by single...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7993095
Blood Advances; Lim KH, Wu JN et. al.

Mar 18th, 2021 - Clonal evolution and heterogeneity in advanced systemic mastocytosis revealed by single-cell DNA sequencing.|2021|Lim KH,Wu JN,Huang TY,Jhuang JY,Chang YC,|

see more →

News  59 results

Gene-targeting therapy shown to reduce mastocytosis symptoms
https://www.mdedge.com/familymedicine/article/219888/asthma/gene-targeting-therapy-shown-reduce-mastocytosis-symptoms?channel=39313
CHEST Physician; Richard Mark Kirkner

Mar 31st, 2020 - A small-molecule kinase inhibitor that targets a gene mutation complicit in systemic mastocytosis has been found to reduce symptoms by about 30%, according to early results of a clinical trial scheduled to be presented at the American Academy of A.

Update on Rosacea Classification and Its Controversies
https://www.mdedge.com/dermatology/article/204310/rosacea/update-rosacea-classification-and-its-controversies/page/0/1?channel=291

Jul 9th, 2019 - However, the Expert Committee still did not define either the length of time of flushing or nontransient erythema. It also did not specify convex surfaces of the face with periocular sparing as the characteristic pattern or provide additional info.

Inhibitor can improve symptoms of systemic mastocytosis
https://www.mdedge.com/hematology-oncology/article/190755/cythemias/inhibitor-can-improve-symptoms-systemic-mastocytosis?channel=50517
Jen Smith

Dec 8th, 2018 - Photo by Jen Smith Jason R. Gotlib, MD SAN DIEGO—The KIT D816V inhibitor avapritinib can improve symptoms of systemic mastocytosis (SM), according to researchers.

A Case of Systemic Mastocytosis With Associated Clonal Hematological Non-Mast Cell Lineage Disease at VA Pittsburgh Healthcare System
https://www.mdedge.com/fedprac/avaho/article/174895/lymphoma-plasma-cell-disorders/case-systemic-mastocytosis-associated
Liman AD, Gandhi A et. al.

Sep 14th, 2018 - Introduction: Systemic mastocytosis (SM) is a rare myeloid neoplasm that is caused by accumulation of abnormal mast cells in the bone marrow, liver, spleen, and skin. The KIT D816V mutation encodes a constitutively activated receptor tyrosine kina.

Avapritinib produces durable responses in SM
https://www.mdedge.com/hematology-oncology/article/184888/leukemia-myelodysplasia-transplantation/avapritinib-produces-durable
HT Staff

Jun 25th, 2018 - Photo from EHA Poster session at the 23rd Congress of the European Hematology Association (EHA) STOCKHOLM—The KIT/PDGFRA inhibitor avapritinib has produced durable responses in patients with systemic mastocytosis (SM). In the phase 1 EXPLORER tria.

see more →

Patient Education  7 results see all →